OPEN END TURBO LONG - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 15:15:06 2024-06-24 EDT | ||
| 23.74 EUR | +2.06% |
|
| Current month | +9.15% | ||
| 1 month | +8.25% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-24 | 23.74 | +2.06% |
| 24-06-21 | 23.26 | -0.60% |
| 24-06-20 | 23.4 | +2.27% |
| 24-06-19 | 22.88 | -0.91% |
| 24-06-18 | 23.09 | -2.57% |
Delayed Quote Börse Stuttgart
Last update June 24, 2024 at 03:15 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MB7TW7 |
| ISIN | DE000MB7TW77 |
| Date issued | 2023-06-22 |
| Strike | 221.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 13.17 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 24.56 € |
|---|---|
| Lowest since issue | 12.43 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
475
USD
Average target price
464
USD
Spread / Average Target
-2.31%
- Stock Market
- Certificates
- Certificat
